USP49 mediates tumor progression and poor prognosis through a YAP1-dependent feedback loop in gastric cancer
- PMID: 35318441
- DOI: 10.1038/s41388-022-02267-0
USP49 mediates tumor progression and poor prognosis through a YAP1-dependent feedback loop in gastric cancer
Abstract
The importance of the Hippo-Yes-associated protein 1 (YAP1) pathway in gastric carcinogenesis and metastasis has attracted considerable research attention; however, the regulatory network of YAP1 in gastric cancer (GC) is not completely understood. In this study, ubiquitin-specific peptidase 49 (USP49) was identified as a novel deubiquitinase of YAP1, knockdown of USP49 inhibited the proliferation, metastasis, chemoresistance, and peritoneal metastasis of GC cells. Overexpression of USP49 showed opposing biological effects. Moreover, USP49 was transcriptionally activated by the YAP1/TEAD4 complex, which formed a positive feedback loop with YAP1 to promote the malignant progression of GC cells. Finally, we collected tissue samples and clinical follow-up information from 482 GC patients. The results showed that USP49 expression was high in GC cells and positively correlated with the expression of YAP1 and its target genes, connective tissue growth factor (CTGF) and cysteine-rich angiogenic inducer 61 (CYR61). Survival and Cox regression analysis showed that high USP49 expression was associated with poor prognosis and was an independent prognostic factor. Moreover, patients with high USP49 and YAP1 expression had extremely short overall survival. The findings of this study reveal that the aberrant activation of the USP49/YAP1 positive feedback loop plays a critical role in the malignant progression of GC, thus providing potential novel prognostic factors and therapeutic targets for GC.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Similar articles
-
YAP1-CPNE3 positive feedback pathway promotes gastric cancer cell progression.Cell Mol Life Sci. 2024 Mar 17;81(1):143. doi: 10.1007/s00018-024-05178-3. Cell Mol Life Sci. 2024. PMID: 38493426 Free PMC article.
-
miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis.Cell Death Dis. 2018 Jan 24;9(2):92. doi: 10.1038/s41419-017-0134-0. Cell Death Dis. 2018. PMID: 29367737 Free PMC article.
-
PKP2 induced by YAP/TEAD4 promotes malignant progression of gastric cancer.Mol Carcinog. 2024 Sep;63(9):1654-1668. doi: 10.1002/mc.23751. Epub 2024 May 28. Mol Carcinog. 2024. PMID: 38804704
-
Increased YAP1 expression is significantly associated with breast cancer progression, metastasis and poor survival.Future Oncol. 2021 Jul;17(21):2725-2734. doi: 10.2217/fon-2020-1080. Epub 2021 Apr 21. Future Oncol. 2021. PMID: 33880946
-
Mechanotransduction and Cytoskeleton Remodeling Shaping YAP1 in Gastric Tumorigenesis.Int J Mol Sci. 2019 Mar 29;20(7):1576. doi: 10.3390/ijms20071576. Int J Mol Sci. 2019. PMID: 30934860 Free PMC article. Review.
Cited by
-
TMEM160 promotes tumor immune evasion and radiotherapy resistance via PD-L1 binding in colorectal cancer.Cell Commun Signal. 2024 Mar 7;22(1):168. doi: 10.1186/s12964-024-01541-w. Cell Commun Signal. 2024. PMID: 38454413 Free PMC article.
-
Cuproptosis related ceRNA axis AC008083.2/miR-142-3p promotes the malignant progression of nasopharyngeal carcinoma through STRN3.PeerJ. 2024 Aug 12;12:e17859. doi: 10.7717/peerj.17859. eCollection 2024. PeerJ. 2024. PMID: 39148682 Free PMC article.
-
YAP1-CPNE3 positive feedback pathway promotes gastric cancer cell progression.Cell Mol Life Sci. 2024 Mar 17;81(1):143. doi: 10.1007/s00018-024-05178-3. Cell Mol Life Sci. 2024. PMID: 38493426 Free PMC article.
-
IGF2BP3-dependent N6-methyladenosine modification of USP49 promotes carboplatin resistance in retinoblastoma by enhancing autophagy via regulating the stabilization of SIRT1.Kaohsiung J Med Sci. 2024 Dec;40(12):1043-1056. doi: 10.1002/kjm2.12902. Epub 2024 Nov 4. Kaohsiung J Med Sci. 2024. PMID: 39497328 Free PMC article.
-
Abnormal activation of RFC3, A YAP1/TEAD downstream target, promotes gastric cancer progression.Int J Clin Oncol. 2024 Apr;29(4):442-455. doi: 10.1007/s10147-024-02478-3. Epub 2024 Feb 21. Int J Clin Oncol. 2024. PMID: 38383698
References
-
- Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet (Lond, Engl). 2020;396:635–48. - DOI
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clinicians. 2021;71:209–49.
-
- Shah MA. Update on metastatic gastric and esophageal cancers. J Clin Oncol: Off J Am Soc Clin Oncol. 2015;33:1760–9. - DOI
-
- Togasaki K, Sugimoto S, Ohta Y, Nanki K, Matano M, Takahashi S, et al. Wnt signaling shapes the histologic variation in diffuse gastric cancer. Gastroenterology. 2021;160:823–30. - DOI
-
- Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer. 2013;13:246–57. - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous